Pathways - manually collected, often from reviews:
OpenBEL Selventa BEL large corpus:
MAPK1
→
F2
(increases, F2 Activity)
Syeda et al., J Biol Chem 2006* Evidence: Thrombin (Fig. 4A) and the PAR-1-selective peptide TFLLRN (not shown) caused a rapid and robust activation of ERK1/2 that was still evident after 2 h but was significantly reduced (p< 0.05) compared with that evident after 10 min.
OpenBEL Selventa BEL large corpus:
MAPK1
→
F2
(increases, F2 Activity, MAPK1 Activity)
Evidence: Platelets contain several potential H-Ras effectors, including PI 3-kinase and Raf-1, and thrombin induces activation of MAP (ERK2) kinase in platelets, possibly through the classical H-Ras pathway.96
BioCarta role of ß-arrestins in the activation and targeting of map kinases:
Ligand/GPCR(+)/Arrestin/RAF1/MEK1/MEK2/ERK1/ERK2 complex (CCL4_EDN1__AGT_CCL11_CXCL12_F2_compound:CAS66575-29-9_compound:CAS745-65-3-ARRB1-RAF1-MAP2K1-MAP2K2-MAPK3-MAPK1)
→
MEK2 (MAP2K2)
(modification, collaborate)
BioCarta role of ß-arrestins in the activation and targeting of map kinases:
Ligand/GPCR(+)/Arrestin/RAF1/MEK1/MEK2/ERK1/ERK2 complex (CCL4_EDN1__AGT_CCL11_CXCL12_F2_compound:CAS66575-29-9_compound:CAS745-65-3-ARRB1-RAF1-MAP2K1-MAP2K2-MAPK3-MAPK1)
→
RAF1
(modification, collaborate)
BioCarta role of ß-arrestins in the activation and targeting of map kinases:
Ligand/GPCR(+)/Arrestin/RAF1/MEK1/MEK2/ERK1/ERK2 complex (CCL4_EDN1__AGT_CCL11_CXCL12_F2_compound:CAS66575-29-9_compound:CAS745-65-3-ARRB1-RAF1-MAP2K1-MAP2K2-MAPK3-MAPK1)
→
ERK2 (MAPK1)
(modification, collaborate)
BioCarta role of ß-arrestins in the activation and targeting of map kinases:
Ligand/GPCR(+)/Arrestin/RAF1/MEK1/MEK2/ERK1/ERK2 complex (CCL4_EDN1__AGT_CCL11_CXCL12_F2_compound:CAS66575-29-9_compound:CAS745-65-3-ARRB1-RAF1-MAP2K1-MAP2K2-MAPK3-MAPK1)
→
Ligand/GPCR(+)/Arrestin complex (CCL4_EDN1__AGT_CCL11_CXCL12_F2_compound:CAS66575-29-9_compound:CAS745-65-3-ARRB1)
(modification, collaborate)
BioCarta role of ß-arrestins in the activation and targeting of map kinases:
Ligand/GPCR(+)/Arrestin/RAF1/MEK1/MEK2/ERK1/ERK2 complex (CCL4_EDN1__AGT_CCL11_CXCL12_F2_compound:CAS66575-29-9_compound:CAS745-65-3-ARRB1-RAF1-MAP2K1-MAP2K2-MAPK3-MAPK1)
→
MEK1 (MAP2K1)
(modification, collaborate)
BioCarta role of ß-arrestins in the activation and targeting of map kinases:
Ligand/GPCR(+)/Arrestin/RAF1/MEK1/MEK2/ERK1/ERK2 complex (CCL4_EDN1__AGT_CCL11_CXCL12_F2_compound:CAS66575-29-9_compound:CAS745-65-3-ARRB1-RAF1-MAP2K1-MAP2K2-MAPK3-MAPK1)
→
ERK1 (MAPK3)
(modification, collaborate)
BioCarta role of ß-arrestins in the activation and targeting of map kinases:
Ligand/GPCR(+)/Arrestin/RAF1/MEK1/MEK2/ERK1/ERK2 complex (CCL4_EDN1__AGT_CCL11_CXCL12_F2_compound:CAS66575-29-9_compound:CAS745-65-3-ARRB1-RAF1-MAP2K1-MAP2K2-MAPK3-MAPK1)
→
dynamin gtpase (DNM1)
(translocation, collaborate)
BioCarta role of ß-arrestins in the activation and targeting of map kinases:
Ligand/GPCR(+)/Arrestin/RAF1/MEK1/MEK2/ERK1/ERK2 complex (CCL4_EDN1__AGT_CCL11_CXCL12_F2_compound:CAS66575-29-9_compound:CAS745-65-3-ARRB1-RAF1-MAP2K1-MAP2K2-MAPK3-MAPK1)
→
Ligand/GPCR(+)/Arrestin/RAF1/MEK1/MEK2/ERK1/ERK2(cy) complex (CCL4_EDN1__AGT_CCL11_CXCL12_F2_compound:CAS66575-29-9_compound:CAS745-65-3-ARRB1-RAF1-MAP2K1-MAP2K2-MAPK3-MAPK1)
(translocation, collaborate)
BioCarta role of ß-arrestins in the activation and targeting of map kinases:
dynamin gtpase (DNM1)
→
Ligand/GPCR(+)/Arrestin/RAF1/MEK1/MEK2/ERK1/ERK2(cy) complex (CCL4_EDN1__AGT_CCL11_CXCL12_F2_compound:CAS66575-29-9_compound:CAS745-65-3-ARRB1-RAF1-MAP2K1-MAP2K2-MAPK3-MAPK1)
(translocation, activates)